FDA allows Curis to resume testing cancer drug
March 31 (Reuters) - Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial.
The company's shares jumped about 22 percent to $3.35 in trading before the bell.
Enrolment for the study was halted after the death of a patient with advanced breast cancer, who experienced acute liver failure about a month after the drug, codenamed CUDC-427, was discontinued.
The trial began in the third quarter of 2013 in patients with advanced solid tumors or lymphomas.
Curis said it planned to continue testing the drug - including in combination with chemotherapy drug, capecitabine - in patients of a type of advanced breast cancer.
The Lexington, Massachusetts-based company's shares closed at $2.75 on the Nasdaq on Friday. (Reporting by Natalie Grover in Bangalore; Editing by Kirti Pandey)
- Exclusive: Angry with Washington, 1 in 4 Americans open to secession
- Scots spurn independence in historic vote, devolution battle begins |
- Alibaba surges 38 percent on massive demand in market debut |
- Eight bodies found after attack on Guinea Ebola education team
- French jets strike in Iraq, expanding U.S.-led campaign against Islamic State |